Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Fenofibrate
Drug ID BADD_D00873
Description Fenofibrate is a fibric acid derivative like [clofibrate] and [gemfibrozil].[A185954] Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.[L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993.[L8585]
Indications and Usage Fenofibrate is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides, and Apo B, and to increase HDL-C adults with primary hypercholesterolemia or mixed dyslipidemia.[L8588,L8591] Fenofibrate is also indicated to treat adults with severe hypertriglyceridemia.[L8588,L8591]
Marketing Status approved
ATC Code C10AB05
DrugBank ID DB01039
KEGG ID D00565
MeSH ID D011345
PubChem ID 3339
TTD Drug ID D07XGR
NDC Product Code 11014-0132; 11722-065; 17337-0019; 58175-0348; 0074-3173; 13668-439; 31722-595; 0115-5522; 42385-950; 50090-6227; 51079-599; 55111-349; 60505-3121; 60687-629; 60760-318; 62332-361; 62332-538; 63304-444; 68180-131; 68180-231; 68462-580; 68462-582; 69238-1263; 71205-050; 71205-190; 71205-666; 71205-949; 0904-7161; 66064-1006; 16714-740; 27437-109; 0115-0522; 0115-5511; 42385-951; 42858-200; 43547-431; 50090-3044; 63304-448; 68071-1712; 70518-2768; 71335-1701; 72789-310; 13668-440; 46708-085; 51407-092; 51407-204; 51655-234; 59651-203; 60687-666; 63187-640; 63304-901; 0378-7100; 68180-389; 68788-8106; 69844-008; 71335-1286; 71335-1292; 71335-2016; 59651-576; 60219-5522; 62332-086; 62332-554; 62559-305; 63187-940; 63304-449; 0378-4391; 68462-581; 69097-894; 69238-1261; 69367-270; 70756-214; 71205-366; 71335-0741; 71335-0891; 82009-060; 11014-0131; 17337-0410; 27437-110; 35561-345; 42291-289; 42385-936; 42858-454; 42858-660; 43975-306; 46708-555; 51407-205; 59651-201; 60687-713; 62332-084; 63187-681; 0378-3066; 68071-2587; 68180-746; 68682-490; 69238-1260; 69315-290; 69367-254; 69844-013; 46708-084; 46708-361; 46708-554; 50268-312; 50268-338; 55700-876; 60219-5511; 60687-655; 62332-360; 62559-461; 68071-2812; 68788-7816; 69097-458; 69367-269; 69844-009; 70518-2349; 0615-8270; 65862-768; 68294-0001; 16714-741; 27241-120; 31722-596; 35561-346; 0115-0511; 42385-935; 42858-067; 46708-086; 46708-350; 46708-360; 50090-6120; 51407-094; 51655-433; 51655-856; 62332-539; 63304-443; 63629-1100; 63629-1101; 63629-9474; 0378-4390; 65862-769; 68071-2540; 68071-2686; 68788-7932; 69097-895; 69844-012; 17337-0430; 0904-7128; 59349-0018; 65977-0074; 16714-739; 35561-347; 0115-0533; 42291-427; 43353-001; 43353-272; 50090-1275; 50090-4698; 50090-5854; 51079-608; 59651-202; 62559-306; 63187-760; 63304-900; 0378-7101; 68012-490; 68084-328; 68180-232; 68180-388; 69315-288; 70934-977; 13672-020; 53747-033; 70966-0021; 13668-438; 27241-117; 27437-108; 42291-290; 43975-305; 43975-444; 51407-091; 60505-3120; 60687-618; 62332-085; 62332-351; 62559-460; 63629-7213; 0378-3065; 68084-827; 68180-130; 69097-896; 69315-287; 69367-268; 70518-2907; 70518-2947; 70518-3370; 71335-0872; 71610-027; 0074-3189; 27241-116; 27241-119; 43353-898; 43598-910; 50090-5244; 51407-090; 55111-395; 62332-350; 62332-555; 63629-1099; 63629-2505; 68012-495; 68084-329; 68682-495; 69097-459; 69238-1262; 69315-289; 70756-215; 71335-1756; 49452-3101; 68543-3173; 68543-3189; 27241-118; 42858-134; 43547-430; 43598-909; 46708-351; 50090-2899; 50090-5796; 50268-313; 51407-093; 51655-009; 51655-554; 59651-575
UNII U202363UOS
Synonyms Fenofibrate | Phenofibrate | Procetofene | Procetofen | Apo-Feno-Micro | Apo Feno Micro | Apo-Fenofibrate | Apo Fenofibrate | CiL | Controlip | durafenat | Fenobeta | Fenofanton | Fenofibrat AbZ | Fenofibrat AL | Fenofibrat AZU | AZU, Fenofibrat | Fenofibrat Heumann | Heumann, Fenofibrat | Fenofibrat Hexal | Hexal, Fenofibrat | Fenofibrat Stada | Stada, Fenofibrat | fenofibrat von ct | Fenofibrat-ratiopharm | Fenofibrat ratiopharm | Fénofibrate MSD | Gen-Fenofibrate | Gen Fenofibrate | LF-178 | LF 178 | LF178 | Lipanthyl | Lipantil | Fenofibrat FPh | Lipidil | Secalip | Supralip | Fénofibrate Debat | Debat, Fénofibrate | Lipidil-Ter | Lipidil Ter | Liparison | Livesan | Lofibra | MTW-Fenofibrat | MTW Fenofibrat | Novo-Fenofibrate | Novo Fenofibrate | Nu-Fenofibrate | Nu Fenofibrate | PMS-Fenofibrate Micro | PMS Fenofibrate Micro | Tricor | Normalip | Antara Micronized Procetofen | Micronized Procetofen, Antara | Procetofen, Antara Micronized
Chemical Information
Molecular Formula C20H21ClO4
CAS Registry Number 49562-28-9
SMILES CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vasodilation procedure25.03.01.001--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Drug resistance08.06.01.0050.000039%Not Available
Hepatic enzyme increased13.03.04.028--Not Available
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Embolism24.01.01.009--
Infestation23.11.01.002; 11.09.01.001--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Decreased appetite08.01.09.028; 14.03.01.005--
Erectile dysfunction21.03.01.007; 19.08.04.0010.000174%
Ill-defined disorder08.01.03.049--Not Available
Myotonia17.05.02.013; 15.05.04.0130.000320%Not Available
Blood disorder01.05.01.004--Not Available
Drug intolerance08.06.01.0130.000557%Not Available
Pulmonary toxicity22.01.02.007; 12.03.01.0130.000158%Not Available
Hepatobiliary disease09.01.08.003--Not Available
Hyperlipidaemia14.08.03.0010.000059%
Renal impairment20.01.03.0100.000118%Not Available
Muscle contracture15.03.05.0240.000079%Not Available
Cystitis noninfective20.03.02.001--
Lichenoid keratosis23.01.01.0040.000324%Not Available
Exfoliative rash23.03.07.0060.000039%Not Available
Chronic kidney disease20.01.03.0170.000039%
Vulvovaginal mycotic infection11.03.05.004; 21.14.02.004--Not Available
Liver injury09.01.07.022; 12.01.17.0120.000059%Not Available
The 10th Page    First    Pre   10 11    Next   Last    Total 11 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene